Journal of Diagnostics Concepts & Practice >
Pleomorphic giant cell adenocarcinoma of prostate: clinicopathological analysis of a case and review of literature
Received date: 2018-08-27
Online published: 2019-04-25
Objective: To study the clinicopathological features, diagnosis, differential diagnosis and prognosis of pleomorphic giant cell adenocarcinoma (PGCA) of prostate. Methods: Clinicopathological and follow-up data of one case of PGCA of prostate were collected and analyzed retrospectively, including immunophenotype. Results: In this case, in addition to the component of conventional high-grade prostate acinar adenocarcinoma, there was also a 5% of PGCA in the prostate tissue. The cells in this area were bizarre, giant, pleomorphic with multinucleate and atypical mitotic figures. Immunohistochemistry showed that the PGCA tumor cells expressed P504S, AE1/AE3, CAM5.2, and partially expressed PSA (60%) but not PSMA, ETS related gene or AR. The response of routine androgen blocking therapy before surgery was poor, and the clinical stage was PT4N0M0, which was highly invasive. Conclusions: PGCA of prostate is a newly defined and extremely rare tumor characterized by pleomorphism. The immunohistochemical expression shows different degrees of loss of prostate-specific antigen, suggesting great heterogeneity of the tumor and poor effect of endocrine therapy, which is different from that of conventional prostate adenocarcinoma. The diagnosis and differential diagnosis is difficult. The clinical course is typically highly aggressive. Therefore, to identify this particular subtype is crucial for clinical follow-up treatment and prognosis.
HE Yanyan, FENG Lijin, WEI Qing . Pleomorphic giant cell adenocarcinoma of prostate: clinicopathological analysis of a case and review of literature[J]. Journal of Diagnostics Concepts & Practice, 2019 , 18(2) : 160 -164 . DOI: 10.16150/j.1671-2870.2019.02.008
[1] | Humphrey PA, Moch H, Cubilla AL, et al. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours[J]. Eur Urol, 2016, 70(1):106-119. |
[2] | Lopez-Beltran A, Eble JN, Bostwick DG. Pleomorphic giant cell carcinoma of the prostate[J]. Arch Pathol Lab Med. 2005 May; 129(5):683-685. |
[3] | Parwani AV, Herawi M, Epstein JI. Pleomorphic giant cell adenocarcinoma of the prostate: report of 6 cases[J]. Am J Surg Pathol. 2006 Oct; 30(10):1254-1259. |
[4] | Larnaudie L, Compérat E, Conort P, et al. HOXB13 a useful marker in pleomorphic giant cell adenocarcinoma of the prostate: a case report and review of the literature[J]. Virchows Arch, 2017, 471(1):133-136. |
[5] | Epstein JI, Egevad L, Amin MB, et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System[J]. Am J Surg Pathol, 2016, 40(2):244-252. |
[6] | Chang J, Pathak AS, Dikranian AH, et al. Benign prostatic stromal hyperplasia with bizarre nuclei[J]. J Urol, 2003, 170(5):1951. |
[7] | Gaudin PB, Rosai J, Epstein JI. Sarcomas and related proliferative lesions of specialized prostatic stroma: a clinicopathologic study of 22 cases[J]. Am J Surg Pathol, 1998, 22(2):148-162. |
[8] | Bostwick DG, Egbert BM, Fajardo LF. Radiation injury of the normal and neoplastic prostate[J]. Am J Surg Pathol, 1982, 6(6):541-551. |
[9] | Shannon RL, Ro JY, Grignon DJ, et al. Sarcomatoid carcinoma of the prostate. A clinicopathologic study of 12 patients[J]. Cancer, 1992, 69(11):2676-2682. |
[10] | Barresi V, Ieni A, Cardia R, et al. HOXB13 as an immunohistochemical marker of prostatic origin in metasta-tic tumors[J]. APMIS, 2016, 124(3):188-193. |
[11] | Varinot J, Cussenot O, Roupret M, et al. HOXB13 is a sensitive and specific marker of prostate cells, useful in distinguishing between carcinomas of prostatic and urothelial origin[J]. Virchows Arch, 2013, 463(6):803-809. |
[12] | Alshenawy HA, Saied E. Do HOXB13 and P63 have a role in differentiating poorly differentiated prostatic carcinoma from urothelial high-grade carcinoma?[J]. APMIS, 2015, 123(9):772-788. |
/
〈 |
|
〉 |